D
Demeter Bio-Tech
Biotech & Life Sciences · China · Founded 2019
ProvideS solutions based on microalgae technology for the sustainable development of society MoreLess
Demeter Biotechnology, operating under the brand name DMT Biotech, specializes in the large-scale production and commercialization of microalgae-based products. Utilizing a proprietary photon carbon smart biomanufacturing platform, the company employs synthetic biology to create specialized algal species. These species are then cultivated using a biological manufacturing system enhanced by artificial intelligence technology.
Demeter's core products include fucoxanthin, EPA (eicosapentaenoic acid), and alternative proteins derived from microalgae. The company aims to capture more than 40% of the global market share in these segments.
Demeter serves a diverse range of clients, including those in the nutraceutical, pharmaceutical, and food industries, who seek sustainable and innovative raw materials. The company operates within the biotechnology and sustainable development markets, focusing on providing eco-friendly solutions.
Demeter's business model revolves around the mass production and sale of high-value microalgae-based raw materials. Revenue is generated through direct sales to industrial clients and partnerships with companies seeking sustainable alternatives to traditional raw materials.
Keywords: microalgae, synthetic biology, AI, fucoxanthin, EPA, alternative protein, biomanufacturing, sustainability, raw materials, biotechnology.
Company overview
Demeter Bio-Tech company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- China
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 24.0
Valuation & funding
Demeter Bio-Tech funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Aug 2022 | $14M | $55M | HSG · Envision Energy | ↗ |
| SPINOUT✓Other financing | Jan 2019 | $0 | — | Chinese Academy Of Sciences | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 2 |
| 2025 | 3 |
| 2024 | 3 |
| 2023 | 4 |
| 2022 | 3 |
Growth signals
Demeter Bio-Tech website traffic
Latest recorded traffic for Demeter Bio-Tech is 90 monthly website visits, down 43.8% over the last three months. Demeter Bio-Tech's team declined 33.3% over the past year.
Comparisons
Demeter Bio-Tech compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Demeter Bio-Tech's talent
Source: Dealroom Talent Intelligence.
Investors
3 investors on Demeter Bio-Tech's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Demeter Bio-Tech has talent and traffic
team presence
In the news
Latest news about Demeter Bio-Tech
Recent press, funding announcements, and product moves mentioning Demeter Bio-Tech — open to read from the original sources.
Market sentiment
What the market is saying about Demeter Bio-Tech
An AI-synthesized read of the highest-engagement posts about Demeter Bio-Tech on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Demeter Bio-Tech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.